359 related articles for article (PubMed ID: 25859291)
1. Polycomb-mediated silencing in neuroendocrine prostate cancer.
Clermont PL; Lin D; Crea F; Wu R; Xue H; Wang Y; Thu KL; Lam WL; Collins CC; Wang Y; Helgason CD
Clin Epigenetics; 2015; 7(1):40. PubMed ID: 25859291
[TBL] [Abstract][Full Text] [Related]
2. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer.
Clermont PL; Crea F; Chiang YT; Lin D; Zhang A; Wang JZ; Parolia A; Wu R; Xue H; Wang Y; Ding J; Thu KL; Lam WL; Shah SP; Collins CC; Wang Y; Helgason CD
Clin Epigenetics; 2016; 8():16. PubMed ID: 26877821
[TBL] [Abstract][Full Text] [Related]
3. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM
Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806
[TBL] [Abstract][Full Text] [Related]
4. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
[TBL] [Abstract][Full Text] [Related]
5. Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer.
Shan J; Al-Muftah MA; Al-Kowari MK; Abuaqel SWJ; Al-Rumaihi K; Al-Bozom I; Li P; Chouchane L
Cell Death Discov; 2019; 5():139. PubMed ID: 31583122
[TBL] [Abstract][Full Text] [Related]
6. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
[TBL] [Abstract][Full Text] [Related]
7. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer.
Crea F; Venalainen E; Ci X; Cheng H; Pikor L; Parolia A; Xue H; Nur Saidy NR; Lin D; Lam W; Collins C; Wang Y
Epigenomics; 2016 May; 8(5):721-31. PubMed ID: 27096814
[TBL] [Abstract][Full Text] [Related]
8. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
10. Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.
Ci X; Hao J; Dong X; Xue H; Wu R; Choi SYC; Haegert AM; Collins CC; Liu X; Lin D; Wang Y
Cells; 2020 Jun; 9(6):. PubMed ID: 32512818
[TBL] [Abstract][Full Text] [Related]
11. LIN28B promotes the development of neuroendocrine prostate cancer.
Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
[TBL] [Abstract][Full Text] [Related]
12. The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms.
Mather RL; Parolia A; Carson SE; Venalainen E; Roig-Carles D; Jaber M; Chu SC; Alborelli I; Wu R; Lin D; Nabavi N; Jachetti E; Colombo MP; Xue H; Pucci P; Ci X; Hawkes C; Li Y; Pandha H; Ulitsky I; Marconett C; Quagliata L; Jiang W; Romero I; Wang Y; Crea F
Mol Oncol; 2021 Jul; 15(7):1921-1941. PubMed ID: 33793068
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
Lee AR; Gan Y; Tang Y; Dong X
EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
[TBL] [Abstract][Full Text] [Related]
14. Treatment-induced neuroendocrine prostate cancer and
Wishahi M
World J Clin Cases; 2024 May; 12(13):2143-2146. PubMed ID: 38808339
[TBL] [Abstract][Full Text] [Related]
15. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Models of Neuroendocrine Prostate Cancer.
Cacciatore A; Albino D; Catapano CV; Carbone GM
Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
Coleman DJ; Sampson DA; Sehrawat A; Kumaraswamy A; Sun D; Wang Y; Schwartzman J; Urrutia J; Lee AR; Coleman IM; Nelson PS; Dong X; Morrissey C; Corey E; Xia Z; Yates JA; Alumkal JJ
Neoplasia; 2020 Jun; 22(6):253-262. PubMed ID: 32403054
[TBL] [Abstract][Full Text] [Related]
18. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
[TBL] [Abstract][Full Text] [Related]
19. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
20. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
